Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
暂无分享,去创建一个
S. Larson | D. Scheinberg | R. Warrell | W. Miller | O. Gansow | R. Finn | J. Jurcic | T. Nikula | P. Caron | E. Papadopoulos | T. Nikula | M. W. Geerlings | Joseph G. Juricic
[1] S. Larson,et al. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. , 1995, Leukemia.
[2] D. Scheinberg,et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Barbui,et al. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia , 1992, The Lancet.
[4] E. Dmitrovsky,et al. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[5] C. Cordon-Cardo,et al. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. , 1989, Leukemia.
[6] D. Scheinberg,et al. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. , 1989, Leukemia.
[7] P. Maslak,et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. , 1994, Leukemia.
[8] D. Scheinberg,et al. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] R Berger,et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. , 1990, Blood.
[10] D. Scheinberg,et al. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] S. Stass,et al. All‐trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia , 1994, Cancer.
[12] A. Scott,et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity , 1994 .
[13] E. Dmitrovsky,et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. , 1993, Blood.
[14] D. Scheinberg,et al. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. , 1992, Cancer research.